idc btig estim compani document
million except per share amount
vigor defens impella underway data headwind look
linger commentari point revenu lower end guidanc rang
reduc guidanc way key question
formal earn call januari look unfortun seem take
time shake neg impact controversi unfavor
aha data novemb januari patient util flat y/i
sequenti decemb gird battl effort roadshow
kol call addit analysi present comprehens impella data user
regul broader clinician commun alreadi motion
educ outreach show sign success one-on-on basi
believ take time damag data undon reduc
revenu estim meaning remov patient procedur
outlook beyond stage think earli determin
time around potenti turnaround model low
point impella patient procedur sequenti ramp procedur
volum throughout maintain neutral rate
long might pain last flat y/i patient usag januari mean
weak start estim procedur y/i
y/i growth octob novemb flat y/i
decemb low-single-digit y/i estim januari flat
februari possibl flat slightli mid-single-digit growth
march y/i procedur growth rate model reason
similarli msd growth rate first half appear feasibl
us stage easi comp help growth rate rebound second
half revis impella revenu forecast
respect prior estim may get anoth updat
procedur trend american colleg cardiolog meet
step ga pedal new trial protect iv rct high-
risk pci develop eight month may start enrol
within next year intend support class guidelin recommend
impella use procedur trial compar high-risk pci
impella use vs high-risk pci without hemodynam support recov iv rct
cardiogen shock compar impella treatment
newsth stemi dtu trial enrol patient
center secur irb approv far japan fewer site
open quarter prepar move post-approv
studi wider launch current center impella fresh launch
site
valuat rate neutral risk discuss
rate neutral believ stori mani posit robust cash high margin potenti
indic expans under-penetrated market high barrier entri howev recent data headwind
uncertainti around time potenti recoveri procedur volum trend give us paus btig provid
price target neutral-r stock risk includ procedur volum reimburs cut slippag product
timelin chang procedur patent litig unsuccess unfavor data competit fda
updat procedur trend
stabil recent declin procedur growth stabl price
expans within current total address market
expans current total address market
key product impella
enabl doctor use
cathet deliv tini heart
pump patient femor
arteri heart impella
move oxygen blood
left ventricl heart
bodi organ reliev
diseas heart help stabil
patient increas blood flow
cut reimburs
report total revenu lower forecast miss split
ou impella sale impella revenu grow y/i impella procedur growth meanwhil
ou impella revenu improv y/i revenu japan site open
hospit vs hospit approv govern
gross margin forecast pressur smartassist launch geograph sale mix
sg spend meaning better model spend lower project
overal ebit margin higher model thank lower oper expens non-gaap ep
beat estim penni lower revenu off-set better oper margin
reduc revenu model toward bottom guidanc rang also cut sale
estim go forward notabl assum return normal procedur pattern back half fiscal
year due lower revenu level go forward reduc gross margin forecast increas oper expens
percentag revenu
actualsbtig estimate varianceestim impella sale trial impella sale revenu net incom bpssg spend bpsr spend bpsebit bpstax bpssourc btig estim compani non- ep add unreal gain compani investmentin rate add etb varianc
rate neutral believ stori mani posit robust cash high margin potenti
indic expans under-penetrated market high barrier entri howev recent data headwind uncertainti
around time potenti recoveri procedur volum trend give us paus btig provid price target
neutral-r stock risk includ procedur volum reimburs cut slippag product timelin chang
procedur patent litig unsuccess unfavor data competit fda
exhibit comp tabl fast-grow med-tech compani
impella sale impella sale net incom ep btig estim compani filingsnewold changentm surgicalisrgneutr inc ingnnot technologiesirtcbuy entxentneutr factset data btig estimatespr ex-amortev/salescagrcompanytickerr ptpricemarket cap
abiom incom product fund total y/i good gross sg amort intangibles- total oper incom loss invest incom incom incom expens pre-tax incom incom gaap net incom gaap share non-gaap non-gaap non-gaap ex select calendar loss net product product product oper ep btig estim compani report
abiom revenu commercialnew impella unit asp stock impella cp cp unit cp asp cp stock impella unit asp stock impella unit asp stock impella rp rp unit rp asp rp stock stock y/i consol instal rate new growth impella impella product trial impella impella product product y/i product btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
